Pacira Pharmaceuticals News and Activities
Presence
Pacira Pharmaceuticals develops and sells non-opioid pain management and regenerative medicine products. It serves hospitals, surgery centers, and healthcare professionals that treat patients before, during, and after medical procedures.
Pacira Pharmaceuticals products and services overview:
- Pain management
- Non opioid drugs
- Local anesthetics
- Regenerative medicine
- Cell therapy
Revenue: ~$700 million
Employees: 900
Headquarters: Parsippany, United States (USA)
Pacira Pharmaceuticals is one of the...
Pacira Pharmaceuticals is a company listed under the stock ticker PCRX (US).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Pacira Pharmaceuticals
Popular executive movements at Pacira Pharmaceuticals
- Thomas Wiggans has joined the company as Director (posted on June 10 2026).
- Christopher Christie has joined the company as Director (posted on June 10 2026).
- Samit Hirawat has joined the company as Director (posted on January 29 2026).
Click here to view some more movements at Pacira Pharmaceuticals
Create your alert
to follow the executive moves at Pacira Pharmaceuticals.
Pharmaceuticals
Pacira Pharmaceuticals has 1,913 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).
Popular M&A news in Pharmaceuticals
- Eli Lilly has acquired Centessa Pharmaceuticals (posted on June 24 2026).
- Polpharma has acquired Biofarm (posted on June 24 2026).
- AbbVie has announced the acquisition of Apogee Therapeutics (posted on June 23 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Pacira Pharmaceuticals
- Pacira BioSciences Reports Second Quarter 2022 Financial Results | Pacira BioSciences, Inc.
- Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference | Pacira BioSciences, Inc.
- Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022 | Pacira BioSciences, Inc.
- Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million | Pacira BioSciences, Inc.
- National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse | Pacira BioSciences, Inc.
- Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022 | Pacira BioSciences, Inc.
- Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference | Pacira BioSciences, Inc.
- Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022 | Pacira BioSciences, Inc.
- Pacira BioSciences to Present at Two Healthcare Conferences in May | Pacira BioSciences, Inc.
- Pacira BioSciences Reports First Quarter 2022 Financial Results | Pacira BioSciences, Inc.
- View more press releases Close
Social media about Pacira Pharmaceuticals
- Pacira Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Pacira Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
